Continuing Nivolumab After Progression Improves Survival in RCC

Video

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.

The continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial was found to extend survival, according to data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 4509).

Median overall survival was 28.1 months for patients who continued to receive treatment vs 15 months for patients who stopped treatment at progression. In this video Saby George, MD, of the Roswell Park Cancer Institute in Buffalo, New York, discusses these results.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content